Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    April 2024
  1. ZHU C, Pang S, Liu J, Duan Q, et al
    Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines.
    Drugs. 2024;84:403-423.
    >> Share

    February 2024
  2. SCHIMMEL J, Epperson LC, Aldy K, Wax P, et al
    Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry.
    Drugs. 2024;84:209-217.
    >> Share

    September 2023
    Remdesivir: A Review in COVID-19.
    Drugs. 2023;83:1215-1237.
    >> Share

    June 2023
  4. POLAK TB, Cucchi DGJ, Schelhaas J, Ahmed SS, et al
    Results from Expanded Access Programs: A Review of Academic Literature.
    Drugs. 2023;83:795-805.
    >> Share

    May 2023
  5. CHEN TY, Wang SI, Hung YM, Hartman JJ, et al
    Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study.
    Drugs. 2023;83:621-632.
    >> Share

    February 2023
  6. KEAM SJ
    Nirsevimab: First Approval.
    Drugs. 2023;83:181-187.
    >> Share

  7. XIE J, Brash JT, Turkmen C, Driessen S, et al
    Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
    Drugs. 2023;83:249-263.
    >> Share

    January 2023
  8. PLOCQUE A, Mitri C, Lefevre C, Tabary O, et al
    Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
    Drugs. 2023;83:1-36.
    >> Share

    August 2022
  9. HOY SM
    Amubarvimab/Romlusevimab: First Approval.
    Drugs. 2022;82:1327-1331.
    >> Share

    July 2022
    Desidustat: First Approval.
    Drugs. 2022;82:1207-1212.
    >> Share

    June 2022
  11. KEAM SJ
    Tixagevimab + Cilgavimab: First Approval.
    Drugs. 2022;82:1001-1010.
    >> Share

  12. KOUFAKIS T, Mustafa OG, Ajjan RA, Garcia-Moll X, et al
    From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
    Drugs. 2022;82:949-955.
    >> Share

    March 2022
  13. LAMB YN
    Nirmatrelvir Plus Ritonavir: First Approval.
    Drugs. 2022 Mar 19. pii: 10.1007/s40265-022-01692.
    >> Share

  14. HEO YA
    Sotrovimab: First Approval.
    Drugs. 2022;82:477-484.
    >> Share

  15. SYED YY
    Molnupiravir: First Approval.
    Drugs. 2022;82:455-460.
    >> Share

    February 2022
  16. MAZZA MG, Vai B, De Picker L, Benedetti F, et al
    Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:349-351.
    >> Share

  17. LENZE EJ, Reiersen AM, Facente SN
    Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:353-354.
    >> Share

    January 2022
  18. RIZK JG, Wenziger C, Tran D, Hashemi L, et al
    Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Drugs. 2022;82:43-54.
    >> Share

    December 2021
  19. FACENTE SN, Reiersen AM, Lenze EJ, Boulware DR, et al
    Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Drugs. 2021;81:2081-2089.
    >> Share

  20. SYED YY
    Regdanvimab: First Approval.
    Drugs. 2021;81:2133-2137.
    >> Share

    November 2021
  21. DEEKS ED
    Casirivimab/Imdevimab: First Approval.
    Drugs. 2021;81:2047-2055.
    >> Share

    September 2021
  22. AHMED N, Pezacki JP
    Reply to Zhang and Zhu "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1693-1695.
    >> Share

  23. ZHANG S, Zhu F
    Comment on: "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1691-1692.
    >> Share

    July 2021
  24. ROE MT, Patrick-Lake B, von Eschenbach AC
    Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.
    Drugs. 2021;81:1235-1237.
    >> Share

    June 2021
  25. VUORIO A, Kovanen PT
    Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
    Drugs. 2021;81:1125-1127.
    >> Share

    April 2021
  26. HEO YA
    Voclosporin: First Approval.
    Drugs. 2021;81:605-610.
    >> Share

  27. HUM C, Loiselle J, Ahmed N, Shaw TA, et al
    MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Drugs. 2021;81:517-531.
    >> Share

  28. TORRES-PENA JD, Perez-Belmonte LM, Fuentes-Jimenez F, Lopez Carmona MD, et al
    Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.
    Drugs. 2021;81:685-695.
    >> Share

    March 2021
  29. LAMB YN
    BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Drugs. 2021;81:495-501.
    >> Share

    December 2020
  30. LIN KJ, Schneeweiss S, Tesfaye H, D'Andrea E, et al
    Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.
    Drugs. 2020;80:1961-1972.
    >> Share

    October 2020
  31. CANTINI F, Goletti D, Petrone L, Najafi Fard S, et al
    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Drugs. 2020 Oct 17. pii: 10.1007/s40265-020-01421.
    >> Share

  32. HAJRA A, Mathai SV, Ball S, Bandyopadhyay D, et al
    Management of Thrombotic Complications in COVID-19: An Update.
    Drugs. 2020;80:1553-1562.
    >> Share

    September 2020
  33. VRACHATIS DA, Giotaki SG, Giannopoulos G, Deftereos S, et al
    Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19".
    Drugs. 2020;80:1499-1500.
    >> Share

  34. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".
    Drugs. 2020;80:1501-1503.
    >> Share

  35. BIANCONI V, Violi F, Fallarino F, Pignatelli P, et al
    Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
    Drugs. 2020;80:1383-1396.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016